Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAVI G004: Safety and Immunogenicity of mRNAs Encoding HIV Immunogens in Healthy Adults
NCT06694753Phase 1Active, not recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mRNA-1645 in human immunodeficiency virus infection (HIV) (8 cohorts), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Incidence of local and systemic reactogenicity and treatment-emergent adverse events and Induction of VRC01- or BG18-class IgG B cell responses at 15.5 weeks. Started Dec 2025; status: active, not recruiting.
02
Drugs
mRNA-1645
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06694753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694753.